SCHEMBL889937

SCHEMBL889937

BC1CC(OC)C(CO)O1

nearest known ligand 0.32

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32
MGAM O43451 2/20 0.32
SI P14410 2/20 0.32
SYNJ2 O15056 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19604050 1.00 PTGS1 (0.32) PTGS1PTGS2MGAMSISYNJ2
SCHEMBL14062453 1.00 PTGS1 (0.32) PTGS1PTGS2MGAMSISYNJ2
SCHEMBL15943758 1.00 PTGS1 (0.32) PTGS1PTGS2MGAMSISYNJ2
SCHEMBL12826389 1.00 PTGS1 (0.32) PTGS1PTGS2MGAMSISYNJ2
SCHEMBL13171605 0.82
SCHEMBL13801502 0.82
SCHEMBL14062508 0.82
SCHEMBL13801500 0.82 SYNJ2 (0.31) SYNJ2
SCHEMBL21412895 0.81
SCHEMBL15096886 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8465921-B2 Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders ELITECH HOLDING B.V. (NL) 2013-06-18 US disclosed
US-8465921-B2 Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders ELITECH HOLDING B.V. (NL) 2013-06-18 US disclosed
US-20110275070-A1 HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS EPOCH PHARMACEUTICALS, INC. 2011-11-10 US disclosed
US-20110275070-A1 HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS EPOCH PHARMACEUTICALS, INC. 2011-11-10 US disclosed
US-7960362-B2 Synthetic agonists of TLR9 IDERA PHARMACEUTICALS, INC. (US) 2011-06-14 US disclosed
US-7863250-B2 An immunostimulatory oligonucleotide having the structure 5'-TCTGTC1GTTCT-X-TCTTGC1TGTCT-5'; wherein X is a glycerol linker and C1 is 1-(2'-deoxy- beta -D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine; cancer, an autoimmune disorder, airway inflammation, asthma, allergy IDERA PHARMACEUTICALS, INC. (US) 2011-01-04 US disclosed
US-7794945-B2 Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders ELITECH HOLDING B.V. (NL) 2010-09-14 US disclosed
US-7794945-B2 Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders ELITECH HOLDING B.V. (NL) 2010-09-14 US disclosed
EP-1144429-B1 HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS EPOCH BIOSCIENCES INC (US) 2009-07-15 EP disclosed
US-7556923-B1 Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders EPOCH BIOSCIENCES, INC. (US) 2009-07-07 US disclosed
US-7556923-B1 Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders EPOCH BIOSCIENCES, INC. (US) 2009-07-07 US disclosed
US-20090053206-A1 NOVEL SYNTHETIC AGONISTS OF TLR9 IDERA PHARMACEUTICALS, INC. 2009-02-26 US disclosed
US-20090048427-A1 HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS EPOCH BIOSCIENCES, INC. (US) 2009-02-19 US disclosed
US-20090048427-A1 HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS EPOCH BIOSCIENCES, INC. (US) 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090053206-A1 NOVEL SYNTHETIC AGONISTS OF TLR9 TLR9, TLR3, TLR7 PTGS1 1269/4885PTGS2 1856/4885MGAM 4352/4885
US-20090048427-A1 HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS DDB1, LIG3, MSH2 PTGS1 3766/4885PTGS2 3852/4885MGAM 713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.